^
Association details:
| Biomarker: | ABL1 exon 4 deletion + ABL1 T315I |
|---|---|
| Cancer: | Acute Lymphocytic Leukemia |
| Drug: | Iclusig (ponatinib) (Multi-tyrosine kinase inhibitor) + Blincyto (blinatumomab) (CD3 agonist, CD19 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Molecular remission after combination therapy with blinatumomab and ponatinib with relapsed/refractory Philadelphia chromosome-positive acute lymphocytic leukemia: two case reports
Published date:
03/25/2021
Excerpt:
A 69-year-old Japanese female with R/R Ph+ ALL...However, she developed a second relapse after acquiring ABL exon4 skipping in addition to T315I. She subsequently received a total of seven cycles of BLIN and ponatinib combination therapy, which resulted in sustained mCR....BLIN + ponatinib combination therapy was highly effective for R/R Ph+ ALL without any incidence of severe adverse events.
DOI:
10.1186/s13256-021-02771-z
